The Latest Convergence of AI & HPC, the 29th HPC Connection Workshop at ISC22
23.5.2022 10:09:00 EEST | Business Wire | Press release
The 29th HPC Connection Workshop (HPCC) will be held online at 2pm (CEST) on May 30, 2022, at ISC22 with the theme "The Latest Convergence of AI & HPC." World renowned experts and industry leaders will introduce the latest in the convergence of AI and HPC.
Featured speakers include:
- Jean-Marc Denis, Chief Strategy Officer of SiPearl, will describe new paradigms and challenges in Exascale era with the perspective of the key decisions made for Rhea processor architecture and design. Rhea is built on Arm's Neoverse V1 processor architecture, but it also has 29 RISC-V cores deployed as controllers. Rhea is planned to be deployed in an European Exascale supercomputer in 2023.
- Radoslav Danilak, CEO of Tachyum, will provide an overview of the features and benefits of Tachyum Prodigy, the world’s first Universal Processor. With 128 64-bit CPU cores operating at up to 5.7GHz, Prodigy not only handles general-purpose computing, HPC, and AI workloads on a single chip, it does so with a power budget that's 10 times lower than that of traditional hardware and at one-third the cost.
- Wolfgang Gentzsch, President of UberCloud, will summarize UberCloud’s 10 year achievements and present several customer use cases, and elaborate on UberCloud’s fully automated, portable, self-service, and multi-cloud engineering platform.
- Shu Yin, Assistant Professor at ShanghaiTech University, will share how to optimize HPC applications from the perspective of I/O, and will demonstrate best practices and use cases.
- Weizheng Lu, Tech Lead of Public Computing Center at Renmin University of China, will talk about Jax-Quant-Finance, and the High Performance Quantitative Library which brings HPC, Deep Learning, and Financial Mathematics together to accelerate financial problems time-to-resolution on heterogeneous platforms.
- Longxiang Li, Senior HPC engineer at Inspur Information, will detail the building of data-driven scientific workflows by coupling HPC with machine learning methods and introduce Inspur’s recent achievements in the fields of materials science, CFD, and ocean modeling.
|
The 29th HPC Connection Workshop Digital 2pm (CEST) May 30, 2022 Online |
|
Agenda |
|
Rhea Processor: Overall Strategic Directions and Specifications Jean-Marc Denis Chief Strategy Officer (CSO), SiPearl |
|
Tachyum Prodigy, The World’s First Universal Processor Radoslav Danilak CEO, Tachyum |
|
10 Year HPC in the Cloud: From Early Cloud Experiments to a Fully Automated Simulation Multi-Cloud Platform for Complex Engineering Workflows Wolfgang Gentzsch President of UberCloud |
|
Optimize HPC applications from the I/O perspectives Shu Yin Assistant Professor, ShanghaiTech University |
|
Jax-Quant-Finance: Bring HPC, Deep Learning and Financials Mathematics together Weizheng Lu Tech Lead of Public Computing Center, Renmin University of China |
|
Building data-driven scientific workflows with machine learning and HPC applications Longxiang Li Senior HPC engineer, Inspur Information |
Click here to register: http://www.asc-events.net/HPCC/ISC22.php
About HPC Connection Workshop
The HPC Connection Workshop is an international High Performance Computing event organized by the Asia Supercomputer Community and Inspur Information. This event takes place three times a year: during ASC in China, ISC in Germany, and SC in the USA. Top researchers and leading professionals from around the world gather at the workshops to discuss the latest developments and disruptive technologies in AI and supercomputing. Visit ASC's website for highlights and videos of the past events: (http://www.asc-events.org/).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220523005035/en/
Contact information
Fiona Liu
media@asc-events.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom